NovoCure Limited - Ordinary Shares (NVCR) Covered Calls

NovoCure Limited is a global oncology company at the forefront of a novel cancer treatment modality called Tumor Treating Fields (TTFields). The company develops, manufactures, and commercializes proprietary devices—including Optune Gio and Optune Lua—that use electric fields tuned to specific frequencies to disrupt cancer cell division. Headquartered in Switzerland, NovoCure focuses on difficult-to-treat solid tumors, including glioblastoma, mesothelioma, and lung cancer.

You can sell covered calls on NovoCure Limited - Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for NVCR (prices last updated Wed 9:50 AM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

NovoCure Limited (NVCR) is a commercial-stage oncology company that pioneered Tumor Treating Fields (TTFields), a non-invasive, antimitotic treatment for solid tumors. TTFields are low-intensity, alternating electric fields that physically exert forces on the highly charged components of dividing cancer cells, leading to mitotic cell death. The company’s flagship product, Optune Gio, is used in combination with chemotherapy for patients with newly diagnosed or recurrent glioblastoma (GBM), providing a significant survival benefit over standard-of-care alone.

The company’s revenue is primarily derived from the United States, Germany, and Japan, with a business model built on a high-margin "prescription-per-month" recurring revenue stream. Patients wear transducer arrays on their skin, which are connected to a portable battery-powered generator. Beyond its core GBM market, NovoCure is aggressively expanding into other high-incidence indications. By early 2026, the firm has secured key approvals and reimbursement in international markets for Optune Lua in non-small cell lung cancer (NSCLC) and has launched Optune Pax for pancreatic cancer. The organization operates a high-touch patient support system, providing 24/7 technical assistance and training to ensure maximum therapy adherence, which is critical to clinical efficacy.

Competitive Landscape

NovoCure essentially created the bioelectronic oncology category, but it now faces competition from emerging technology startups and traditional pharmaceutical giants. Competition in the 2026 landscape is focused on patient "usability"—specifically reducing the size and weight of the hardware—and the integration of TTFields with new immunotherapy drugs.

1. Bristol Myers Squibb: A major competitor in the oncology space whose immunotherapies (like Opdivo) are frequently studied in combination or competition with TTFields in lung cancer.
2. Merck & Co. (MRK): The manufacturer of Keytruda, which represents both a competitive benchmark and a primary clinical trial partner for NovoCure’s combo-therapy strategy.
3. AstraZeneca: A leader in lung cancer treatment that competes for institutional focus and patient share in the advanced NSCLC market.
4. LivaNova: A medical device peer in the neuromodulation and bioelectronic space that serves as a benchmark for institutional medical technology valuation.
5. QV Bioelectronics: A private emerging rival developing "implanted" TTFields arrays to improve patient adherence and eliminate the need for external head-shaving.

Strategic Outlook and Innovation

The strategic focus for 2026 is NovoCure’s "Torso Launch"—the commercial scale-up of its therapy for pancreatic and lung cancers. Management is targeting a total addressable market (TAM) expansion of over 10x compared to its original glioblastoma niche. A major clinical milestone expected in Q2 2026 is the topline data from the TRIDENT trial, which could move TTFields into the "front-line" setting for newly diagnosed GBM, significantly extending the duration of therapy per patient. Financed by a robust cash position following its 2025 debt restructuring, the firm is striving for cash-flow break-even by 2027.

Innovation at NovoCure is centered on "next-generation" transducer arrays and software-driven treatment planning. The company has introduced "Thinner" and more flexible electrodes to improve comfort and reduce skin irritation, which are the primary drivers of therapy discontinuation. Additionally, the company is utilizing AI-based modeling to personalize the "dose" of electric fields based on a patient’s specific anatomy and tumor location. By integrating its digital "MyNovoCure" patient app with real-time adherence tracking, the firm aims to prove that higher usage leads to better survival outcomes, thereby securing more favorable long-term reimbursement rates from global health authorities.

Want more examples? NVAX Covered Calls | NVD Covered Calls